Pharma Capital

Genedrive secures CE mark for breakthrough diagnostic Hepatitis-C test

David Budd, chief executive of Genedrive PLC (LON:GDR), tells Proactive they've achieved a landmark for their breakthrough rapid diagnostic test for Hepatitis-C with the awarding of the CE mark.

It allows for introduction of the test into Europe as well as low and middle income countries that accept CE certification under their national regulations.

 

View full GDR profile

Genedrive PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.